Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction.

• Status: Unknown status
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Intracoronary bolus Abciximab single is non-inferior to intravenous and continuous 12- hours infusion in the size reduction of infarction on cardiac magnetic resonance in Non-ST elevation Myocardial infarction.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Collaborator: Seoul National University Bundang Hospital
• Treatments: Abciximab; Antibodies, Monoclonal; Immunoglobulin Fab Fragments; Krestin; polysaccharide-K

Criteria

Inclusion Criteria:

• non-ST segment elevation acute myocardial infarction

• within 48 hours presence of chest pain

• Troponin-T or I positive before CAG

• First myocardial infarction

• will be performed coronary angioplasty

Exclusion Criteria:

• under 18 years of age,80 years or older

• Bleeding tendency

• History of major surgery within 4 weeks

• Major stroke within 2 years

• Thrombocytopenia (<120,000 / uL)

• Cardiogenic shock

• Known allergy to aspirin, heparin, or abciximab

• Contraindication of MRI at study entry (implanted pacemakers, defibrillators, intracranial metallic implants etc)

• Chronic atrial fibrillation

• Pregnancy